These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 37837240)
21. Can increasing the dose of radiation by HDR brachytherapy boost following pre operative chemoradiotherapy for advanced rectal cancer improve surgical outcomes? Sun Myint A; Mukhopadhyay T; Ramani VS; Perkins K; Snee AJ; Jelley F; Wong H; Lee CD Colorectal Dis; 2010 Aug; 12 Suppl 2():30-6. PubMed ID: 20618365 [TBL] [Abstract][Full Text] [Related]
22. Preoperative Intensified Chemoradiation with Intensity-Modulated Radiotherapy and Simultaneous Integrated Boost Combined with Capecitabine in Locally Advanced Rectal Cancer: Long-Term Outcomes of a Real-Life Multicenter Study. Lupattelli M; Palazzari E; Polesel J; Chiloiro G; Angelicone I; Panni V; Caravatta L; Di Biase S; Macchia G; Niespolo RM; Franco P; Epifani V; Meldolesi E; de Giacomo F; Lucarelli M; Montesi G; Mantello G; Innocente R; Osti MF; Gambacorta MA; Aristei C; De Paoli A Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067405 [TBL] [Abstract][Full Text] [Related]
23. Salvage Surgery With Organ Preservation for Patients With Local Regrowth After Watch and Wait: Is It Still Possible? Fernandez LM; Figueiredo NL; Habr-Gama A; São Julião GP; Vieira P; Vailati BB; Nasir I; Parés O; Santiago I; Castillo-Martin M; Carvalho C; Parvaiz A; Perez RO Dis Colon Rectum; 2020 Aug; 63(8):1053-1062. PubMed ID: 32692070 [TBL] [Abstract][Full Text] [Related]
25. [Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial]. Wang L; Zhao YM; Sun TT; Xu YL; Li SJ; Zhang XY; Cai Y; Li YH; Li ZW; Chen PJ; Peng YF; Wang WH; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):258-265. PubMed ID: 32192305 [No Abstract] [Full Text] [Related]
26. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T Serra-Aracil X; Pericay C; Golda T; Mora L; Targarona E; Delgado S; Reina A; Vallribera F; Enriquez-Navascues JM; Serra-Pla S; Garcia-Pacheco JC; Int J Colorectal Dis; 2018 Feb; 33(2):241-249. PubMed ID: 29234923 [TBL] [Abstract][Full Text] [Related]
27. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Rullier E; Rouanet P; Tuech JJ; Valverde A; Lelong B; Rivoire M; Faucheron JL; Jafari M; Portier G; Meunier B; Sileznieff I; Prudhomme M; Marchal F; Pocard M; Pezet D; Rullier A; Vendrely V; Denost Q; Asselineau J; Doussau A Lancet; 2017 Jul; 390(10093):469-479. PubMed ID: 28601342 [TBL] [Abstract][Full Text] [Related]
28. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234). Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW; Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394 [TBL] [Abstract][Full Text] [Related]
29. Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients. Frin AC; Evesque L; Gal J; Benezery K; François E; Gugenheim J; Benizri E; Château Y; Marcié S; Doyen J; Gérard JP Eur J Cancer; 2017 Feb; 72():124-136. PubMed ID: 28027515 [TBL] [Abstract][Full Text] [Related]
30. Factors that influence the adequacy of total mesorectal excision for rectal cancer. Jeyarajah S; Sutton CD; Miller AS; Hemingway D; Colorectal Dis; 2007 Nov; 9(9):808-15. PubMed ID: 17441969 [TBL] [Abstract][Full Text] [Related]
31. Role of radiotherapy in the treatment of rectal cancer in older patients. Myint AS; Gérard JP Eur J Surg Oncol; 2020 Mar; 46(3):349-357. PubMed ID: 31926607 [TBL] [Abstract][Full Text] [Related]
32. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience. Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909 [TBL] [Abstract][Full Text] [Related]
33. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer. Creavin B; Ryan E; Martin ST; Hanly A; O'Connell PR; Sheahan K; Winter DC Br J Cancer; 2017 Jan; 116(2):169-174. PubMed ID: 27997526 [TBL] [Abstract][Full Text] [Related]
34. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J; BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495 [TBL] [Abstract][Full Text] [Related]
35. Sequence of Contact X-ray Brachytherapy (CXB) and External Beam Radiation (EBRT) in organ-preserving treatment for small rectal cancer. Than NW; Pritchard DM; Hughes DM; Duckworth CA; Wong H; Haq MU; Sripadam R; Myint AS Radiother Oncol; 2024 Oct; 199():110465. PubMed ID: 39074538 [TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes by a transanal approach to total mesorectal excision for rectal cancer. Marks JH; Myers EA; Zeger EL; Denittis AS; Gummadi M; Marks GJ Surg Endosc; 2017 Dec; 31(12):5248-5257. PubMed ID: 28643051 [TBL] [Abstract][Full Text] [Related]
37. Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial. Marchegiani F; Palatucci V; Capelli G; Guerrieri M; Belluco C; Rega D; Morpurgo E; Coco C; Restivo A; De Franciscis S; Aschele C; Perin A; Bonomo M; Muratore A; Spinelli A; Ramuscello S; Bergamo F; Montesi G; Spolverato G; Del Bianco P; Gambacorta MA; Delrio P; Pucciarelli S Ann Surg Oncol; 2022 Mar; 29(3):1880-1889. PubMed ID: 34855063 [TBL] [Abstract][Full Text] [Related]
38. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial. Verweij ME; Tanaka MD; Kensen CM; van der Heide UA; Marijnen CAM; Janssen T; Vijlbrief T; van Grevenstein WMU; Moons LMG; Koopman M; Lacle MM; Braat MNGJA; Chalabi M; Maas M; Huibregtse IL; Snaebjornsson P; Grotenhuis BA; Fijneman R; Consten E; Pronk A; Smits AB; Heikens JT; Eijkelenkamp H; Elias SG; Verkooijen HM; Schoenmakers MMC; Meijer GJ; Intven M; Peters FP BMJ Open; 2023 Jun; 13(6):e065010. PubMed ID: 37321815 [TBL] [Abstract][Full Text] [Related]
39. Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence. Benezery K; Montagne L; Evesque L; Schiappa R; Hannoun-Levi JM; Francois E; Thamphya B; Gerard JP Clin Transl Radiat Oncol; 2020 Sep; 24():92-98. PubMed ID: 32695890 [TBL] [Abstract][Full Text] [Related]
40. Total neoadjuvant therapy followed by a watch-and-wait strategy for patients with rectal cancer (TOWARd): protocol for single-arm phase II/III confirmatory trial (JCOG2010). Hashimoto T; Tsukamoto S; Murofushi K; Ito Y; Hirano H; Tsukada Y; Sasaki K; Mizusawa J; Fukuda H; Takashima A; Kanemitsu Y BJS Open; 2023 Nov; 7(6):. PubMed ID: 37931233 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]